Company news
Medincell Sa (EURONEXT:MEDCL) news
Every Medincell Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Medincell to Participate in Upcoming Investor Conferences
September 9, 2026
Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
September 8, 2026
Medincell Appoints Edna Venneker, MD, as Chief Medical Officer
September 1, 2026
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
July 29, 2026
Medincell Continues to Strengthen and Renew Its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg
July 28, 2026
Medincell Aligns Debt Maturity With Its Expected Revenue Growth Trajectory
July 15, 2026
Medincell: Half-Year Liquidity Contract Statement
July 6, 2026
Medincell Reports FY 2025-26 Annual Results
June 16, 2026
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
May 28, 2026
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
May 26, 2026
Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
April 29, 2026
Degroof Petercam Initiates Medincell’s Coverage with a "Buy" Recommendation
April 22, 2026
Leerink Partners Initiates Medincell’s Coverage with a "Outperform" Recommendation
April 21, 2026
Medincell to Host an Online R&D Day on Tuesday, May 12, 2026
April 16, 2026
EIB Waives its Right to Cash Settlement on Medincell Warrants
March 26, 2026
Medincell Announces Successful c. €48 Million Private Placement
March 6, 2026
Medincell Launches a Private Placement for International Institutional Investors
March 5, 2026
Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026
March 4, 2026
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
February 24, 2026
Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable S...
February 20, 2026
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (...
February 20, 2026
Medincell’s ISS ESG Corporate Rating Upgraded
February 10, 2026
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
January 28, 2026
Medincell: Half-year Liquidity Contract Statement
January 20, 2026
Medincell: Publication of the 2026 Financial Calendar
January 12, 2026
Medincell Publishes its Consolidated Half-Year Financial Results
December 9, 2025
Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025
December 1, 2025
Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference
November 27, 2025
Medincell Awarded New Grant to Fight Malaria
November 24, 2025
Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025)
November 13, 2025
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
November 11, 2025
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
November 10, 2025
Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)
November 6, 2025
Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
October 22, 2025
Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Liv...
October 10, 2025
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bi...
October 10, 2025
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
September 23, 2025
Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors
September 12, 2025
Medincell: UZEDY® Approved in South Korea Following Successful US Launch
September 10, 2025
Medincell to Present at the H.C. Wainwright 27th Global Investment Conference and Participate in the Morgan Stanley 23rd Global Healthcar...
September 5, 2025
Medincell: Reminder of the Participation Terms in the Combined General Meeting
September 3, 2025
Medincell: Notice of the 2025 Annual General Meeting Published
August 4, 2025
Medincell Announces the Availability of its 2024-25 Universal Registration Document including the Annual Financial and CSR Reports
July 30, 2025
Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch
July 29, 2025
Medincell Publishes its Consolidated Annual Financial Results
June 17, 2025
Medincell to Present 2024-2025 Annual Results on June 17, 2025
June 10, 2025
Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025
May 28, 2025
Truist Securities Initiates Medincell’s Coverage with a "Buy" Recommendation
May 28, 2025